Nucleoside News and Research

RSS
ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

HIV drugs could be harnessed to treat leading cause of blindness

HIV drugs could be harnessed to treat leading cause of blindness

New oral medication shows promise in treating fibromyalgia

New oral medication shows promise in treating fibromyalgia

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

CleveXel Pharma receives license for two new oncology patents

CleveXel Pharma receives license for two new oncology patents

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

New treatment fights respiratory syncytial virus in children

New treatment fights respiratory syncytial virus in children

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Merck enters into definitive agreement with Idenix

Merck enters into definitive agreement with Idenix

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

TSRI scientists create bacteria with expanded DNA code

TSRI scientists create bacteria with expanded DNA code

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

Study: New combination therapy to treat chronic hepatitis C

Study: New combination therapy to treat chronic hepatitis C

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB